Valerio Therapeutics S.A.
ALVIO.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | -0.4% | 24.7% | -64.5% | – |
| Cost of Goods Sold | €0 | €0 | €0 | €0 |
| Gross Profit | €0 | €0 | €0 | €0 |
| % Margin | 71.4% | 70.4% | 64.4% | 90.9% |
| R&D Expenses | €0 | €0 | €0 | €0 |
| G&A Expenses | €0 | €0 | €0 | €0 |
| SG&A Expenses | €0 | €0 | €0 | €0 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €0 |
| Other Operating Expenses | €0 | €0 | €0 | €0 |
| Operating Expenses | €0 | €0 | €0 | €0 |
| Operating Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | -919.6% | -1,127.1% | -1,186.1% | -180.4% |
| Other Income/Exp. Net | -€0 | -€0 | -€0 | -€0 |
| Pre-Tax Income | -€0 | -€0 | -€0 | -€0 |
| Tax Expense | €0 | €0 | €0 | €0 |
| Net Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | -1,334.7% | -1,130.2% | -1,355.6% | -146.2% |
| EPS | -0.16 | -0.15 | -0.18 | -0.067 |
| % Growth | -6.7% | 16.7% | -167.5% | – |
| EPS Diluted | -0.16 | -0.15 | -0.18 | -0.067 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €0 | €0 | €0 |
| Interest Expense | €0 | €0 | €0 | €0 |
| Depreciation & Amortization | €0 | €0 | €0 | €0 |
| EBITDA | -€0 | -€0 | -€0 | -€0 |
| % Margin | -672.7% | -1,024.7% | -1,180.7% | -144.2% |